By combining structural insights with our antibody drug discovery platform and deep understanding of the underlying biology, our scientific outlook is all-encompassing. We consider ideas, findings, and beliefs about validated targets (past and present) and extend them with our critical science to realize great pharmacological potential.
Structural Insights & the Growth Factor Precursor
Unlike traditional approaches, we target growth factors in their inactive precursor, or latent, forms to selectively regulate their activity in the microenvironment of cells and tissues. We applied this extraordinary selectivity across a number of growth factors, including to transforming growth factor beta (TGFβ), and are on the path to achieving novel discoveries.
Learn More About Structural Insights and the Growth Factor Precursor
Technology Platform
Our proprietary platform aids in our development of antibody drugs that apply to targets living in the scientific crossroads of biologically understood and structurally misunderstood.
Recent Publications
View More PublicationsJuly 22, 2024
Frontiers in Neurology
Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study
July 9, 2024
Science Signaling
An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis
February 9, 2024
Neurology
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
Recent Posters
View More PostersNovember 2024
Society for Immunotherapy of Cancer (SITC) 2024
DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor–resistant advanced cancers
November 2024
ObesityWeek 2024
SRK-439 Selectively Inhibits Myostatin to Promote Healthy Body Composition During Metformin Therapy
October 2024
World Muscle Society Annual Congress
Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: Results from the 48-month TOPAZ study
Partnerships
Help us shed light on the subject. Collaborate with us to uncover enlightened solutions for patients.
“We’re passionate for all
the right reasons.”
Stefan Wawersik
Director, Bioanalytical & Translational Technologies
Join Our Team
Join Our Team
We’re a group of thinkers and doers who fight disease from a new angle.